Abstract
Crizanlizumab (Adakveo (R); crizanlizumab-tmca) is an intravenously administered monoclonal antibody developed by Novartis Pharmaceuticals for the pre......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
